Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study.
Journal
Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055
Informations de publication
Date de publication:
12 11 2021
12 11 2021
Historique:
received:
19
05
2021
revised:
07
09
2021
accepted:
27
09
2021
pubmed:
5
10
2021
medline:
31
12
2021
entrez:
4
10
2021
Statut:
ppublish
Résumé
The prognostic impact of insulin-like growth factor binding protein 7 (IGFBP7) in breast cancer is unclear. Host factors, including lifestyle, anthropometry and metabolic profile, might influence tumor-specific IGFBP7. This study aimed to investigate whether IGFBP7 levels and messenger ribonucleic acid (mRNA) expression are associated with the patient and tumor characteristics and prognosis in breast cancer. Patients with primary breast cancer in Lund, Sweden, were included preoperatively in the study between 2002 and 2012 (n = 1018). Tumor-specific IGFBP7 protein levels were evaluated with immunohistochemistry using tissue microarrays in tumors from 878 patients. IGFBP7 mRNA expression and its corresponding clinical data were obtained from The Cancer Genome Atlas and analyzed for 809 patients. Tumor-specific IGFBP7 protein levels were categorized based on Histo 300 scores into IGFBP7low (6.2%), IGFBP7intermediate (75.7%) and IGFBP7high (18.1%). Both low IGFBP7 protein levels and mRNA expression were associated with less aggressive tumor characteristics. Overall, IGFBP7low conferred low recurrence risk. The prognostic impact of IGFBP7high varied according to any alcohol consumption and tamoxifen treatment. IGFBP7high was associated with low recurrence risk in alcohol consumers but high recurrence risk in alcohol abstainers (Pinteraction= 0.039). Moreover, the combination of IGFBP7high and estrogen receptor-positive tumors was associated with low recurrence risk only in tamoxifen-treated patients (Pinteraction= 0.029). To conclude, IGFBP7low might be a good, independent prognosticator in breast cancer. The prognostic impact of IGFBP7high depends on host factors and treatment. IGFBP7 merits further investigation to confirm whether it could be a suitable biomarker for treatment selection.
Identifiants
pubmed: 34606580
pii: 6380882
doi: 10.1093/carcin/bgab090
pmc: PMC8598394
doi:
Substances chimiques
Insulin-Like Growth Factor Binding Proteins
0
RNA, Messenger
0
Receptors, Estrogen
0
Receptors, Progesterone
0
insulin-like growth factor binding protein-related protein 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1314-1325Subventions
Organisme : Swedish Cancer Society
ID : CAN 2017/368
Organisme : Faculty of Medicine at Lund University
Organisme : Mrs Berta Kamprad Foundation
Organisme : South Swedish Health Care Region
ID : ALF 40620
Organisme : Skåne university hospital fund
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
Cancer Prev Res (Phila). 2012 May;5(5):735-45
pubmed: 22401981
Gynecol Endocrinol. 2005 Mar;20(3):176-82
pubmed: 16019358
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):232-40
pubmed: 17055257
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Virchows Arch. 2020 Aug;477(2):317-320
pubmed: 32080761
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96
pubmed: 19336542
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
Sci Rep. 2017 Jan 12;7:40138
pubmed: 28079144
Oncol Rep. 2019 Nov;42(5):1935-1945
pubmed: 31545454
Oncogene. 2001 Jun 14;20(27):3497-505
pubmed: 11429696
Semin Diagn Pathol. 1984 Nov;1(4):297-308
pubmed: 6400637
Control Clin Trials. 1998 Dec;19(6):589-601
pubmed: 9875838
J Mol Endocrinol. 2018 Jun 13;61(4):R133-R160
pubmed: 29899079
Breast Cancer Res Treat. 2012 Jun;133(2):563-73
pubmed: 21997538
Front Oncol. 2021 Mar 09;11:626058
pubmed: 33767994
Breast Cancer Res Treat. 2011 Apr;126(2):373-84
pubmed: 20464481
Front Oncol. 2020 Feb 06;10:80
pubmed: 32117735
Growth Horm IGF Res. 2002 Aug;12(4):193-7
pubmed: 12175651
Cancer Causes Control. 2018 Jul;29(7):643-656
pubmed: 29804217
Springerplus. 2014 May 22;3:261
pubmed: 24892005
Med Hypotheses. 1999 Jun;52(6):491-6
pubmed: 10459827
Cancer Lett. 2003 Jun 10;195(2):127-37
pubmed: 12767520
Cancer Res. 1993 Apr 15;53(8):1727-30
pubmed: 8467486
Sci Rep. 2015 May 18;5:10227
pubmed: 25984973
Br J Cancer. 2016 Jul 26;115(3):382-90
pubmed: 27280635
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2013 May 21;8(5):e62642
pubmed: 23704881
Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):377-84
pubmed: 11319179
Clin Cancer Res. 2015 Apr 15;21(8):1877-87
pubmed: 25691730
Int J Cancer. 2020 Apr 15;146(8):2348-2359
pubmed: 31490549
Cancer Causes Control. 2012 Aug;23(8):1307-16
pubmed: 22695757
Oncotarget. 2017 Feb 7;8(6):9093-9107
pubmed: 28030849
Breast Cancer. 2019 May;26(3):272-281
pubmed: 30328006
Sci Signal. 2012 Dec 18;5(255):ra92
pubmed: 23250396
Mol Cell Endocrinol. 2021 May 1;527:111213
pubmed: 33607269
Cancer Causes Control. 2019 Nov;30(11):1157-1170
pubmed: 31515643
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:220-34
pubmed: 26455641
Sci Rep. 2020 Apr 14;10(1):6429
pubmed: 32286426
Dtsch Arztebl Int. 2010 Jan;107(4):50-6
pubmed: 20165700
Clin Cancer Res. 2007 Jun 1;13(11):3164-73
pubmed: 17545519
Front Oncol. 2020 May 15;10:727
pubmed: 32500027
Am J Clin Nutr. 2005 Feb;81(2):503-7
pubmed: 15699241
Breast Cancer Res Treat. 1998 Feb;47(3):283-93
pubmed: 9516082
Anticancer Res. 2003 May-Jun;23(3A):2043-51
pubmed: 12894577
Front Endocrinol (Lausanne). 2015 Mar 06;6:30
pubmed: 25798130
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Diabetes. 2006 Aug;55(8):2333-9
pubmed: 16873698
Oncogene. 1998 May 14;16(19):2459-67
pubmed: 9627112